Inhibrx Files for $75 Million IPO

Clinical-stage biotech, InHibrx filed the paperwork for its IPO. The company will raise up to $74,750,000 and intends to trade on NASDAQ under the symbol, “INBX.” Inhibrx is based in La Jolla, CA and has built a pipeline focused on oncology, orphan diseases and infectious diseases.